Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
saRNA can address shortcomings of mRNA by decreasing the number of doses and administration frequency, mitigating side effects and bolstering manufacturing capacity.
“saRNA can address the shortcomings of mRNA by decreasing the number of doses and the administration frequency, which will mitigate side effects8–10 and bolster manufacturing capacity”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [10]
The “Potential impact of anti-PEG antibodies” section reports a correlation between anti-PEG antibodies and systemic reactogenicity after two mRNA vaccine doses, and raises a concern about further booster doses. It does not show that saRNA reduces the number or frequency of doses or that doing so mitigates side effects; it also does not address manufacturing capacity. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 11 · Cited by 201
- Authors
- Ju, Y., Carreño, J. M., Simon, V., Dawson, K., Krammer, F., & Kent, S. J.
- Affiliations
- The University of Melbourne (AU)
- Icahn School of Medicine at Mount Sinai (US)
- University College Dublin (IE)
- Corresponding author
- Krammer, Florian
- Kent, Stephen J.
- Venue
- Nature Reviews Immunology
- Published
- 2022-12-20
- Volume
- 23
- Issue
- 3
- Pages
- 135-136
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC9764299
- OpenAlex
- W4312211314
- Cited by
- 201
- References
- 11
- Citations by year
- 2026: 53 · 2025: 58 · 2024: 64 · 2023: 26
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Surgery › Heparin-Induced Thrombocytopenia and Thrombosis
- Keywords
- anti-PEG antibodies, polyethylene glycol, COVID-19 mRNA vaccine, COVID-19 vaccines, lipid nanoparticles, vaccine reactogenicity, drug clearance, vaccine-induced immune response
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, Vaccines, Synthetic, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
